Cataract News and Research

Latest Cataract News and Research

Common myths about children's eye health and the medical reality behind them

Many parents grew up with medical adages or advice that have since been proven by scientists to be incorrect or outdated. Here are five common myths about children's eye health and the medical reality behind them, prepared by the physicians at The Vision Center at Childrens Hospital Los Angeles.

12 Oct 2009

Roche and Genentech obtain license to use SurModics’ drug delivery system

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has signed a License and Development Agreement with Roche and Genentech, Inc., a wholly-owned member of the Roche Group.

7 Oct 2009

Government of Alberta reimburses first medication to improve vision and restore quality of life

Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.

6 Oct 2009

Genentech announces two Phase III study results of Lucentis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.

5 Oct 2009

Nasdaq issues TLC Vision a noncompliance letter regarding minimum bid price

TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").

23 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, according to two reports in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

15 Sep 2009

Presbia unveils implantable micro-lens treatment for presbyopia

Presbia Coöperatief U.A., an early-stage company focused on surgical solutions for presbyopia, today announced that it will unveil a breakthrough implantable micro-lens treatment for presbyopia at the European Society of Cataract and Refractive Surgery Congress (ESCRS) beginning Sept. 12 in Barcelona.

10 Sep 2009

Majority of surgical patients would consider an unsupervised trainee doctor to perform their operation: Survey

Three-quarters of surgical patients would consider allowing a competent unsupervised trainee junior doctor perform their entire operation if it meant they could have it done more quickly, according to a survey published in the September issue of BJUI.

9 Sep 2009

1.4 million Nigerians over the age of 40 will become blind by 2020: Study

By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.

9 Sep 2009

Preliminary Phase 3 clinical study results of T-Pred released

ISTA Pharmaceuticals, Inc., today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

9 Sep 2009

Abbott to acquire Visiogen for $400 million in cash

Abbott (NYSE: ABT) announced today a definitive agreement to acquire Visiogen, Inc. for $400 million in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.

3 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009

Chlorella green food sourced from algae contains a wide range of essential nutrients

"While we can still take advantage of summer's fresh produce, ensuring a consistent supply of whole foods throughout the year can reap benefits for those focused on aging as healthfully as possible," says Michael E. Rosenbaum, M.D. "Chlorella, a super green food sourced from a fresh water algae, contains the widest range of essential nutrients available in any single food source, including potassium, all B vitamins, magnesium, zinc, iron and 18 vital amino acids." Though beneficial for all life stages, Sun Chlorella can especially help aging adults thanks to these health rewards.

1 Sep 2009

Vision-related patient-reported outcomes used for improving medical product labeling in ophthalmology

The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring an October 13 conference to determine how vision-related patient-reported outcomes might be used to improve medical product labeling in ophthalmology.

26 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Forty-six uninsured San Diego County patients will receive donated outpatient surgeries and procedures on Saturday, August 22, 2009, through an ongoing partnership between Project Access San Diego (PASD), a program of the San Diego County Medical Society Foundation, Kaiser Permanente and the Alliance Healthcare Foundation. PASD mobilizes medical volunteers to provide free surgeries and procedures to uninsured San Diegans.

19 Aug 2009

Heat shock proteins provide protection against cataracts

The human eye lens consists of a highly concentrated mix of several proteins. Protective proteins prevent these proteins from aggregating and clumping. If this protective function fails, the lens blurs and the patient develops cataracts. Two research groups at the Department of Chemistry of the Technische Universitaet Muenchen (TUM) have succeeded in explaining the molecular architecture of this kind of protective protein.

31 Jul 2009

Discovery of genetic link to age-related cataracts

Bing-Cheng Wang, Ph.D., Case Western Reserve University School of Medicine professor of pharmacology and senior staff scientist at MetroHealth Medical Center, and Sudha K. Iyengar, Ph.D. professor of genetic and molecular epidemiology at Case Western Reserve University School of Medicine, have discovered the first gene associated with the formation of age-related cataracts, a leading causes of blindness.

31 Jul 2009

Americans living with no insurance, or less insurance, during recession

Decisions about forgoing care because of the cost for the long-term uninsured have been a way of life, "but for a sizable group, being without a job and insurance is a new, deeply distressing condition," The Milwaukee Journal-Sentinel reports.

20 Jul 2009